Stockscreener 앱 받기
11.79
0.08%
-0.01
전일 마감가:
$11.80
열려 있는:
$11.8
하루 거래량:
3.23M
Relative Volume:
1.19
시가총액:
$9.82B
수익:
$3.81B
순이익/손실:
$485.75M
주가수익비율:
20.07
EPS:
0.5873
순현금흐름:
$175.50M
1주 성능:
-6.43%
1개월 성능:
-19.58%
6개월 성능:
-13.82%
1년 성능:
-19.85%
1일 변동 폭
$11.68
$11.98
1주일 범위
$11.36
$12.74
52주 변동 폭
$11.36
$15.67
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
명칭
Dr Reddys Laboratories Ltd Adr
전화
-
주소
-
Compare RDY vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
11.79 | 9.82B | 3.81B | 485.75M | 175.50M | 0.5873 |
TAK
Takeda Pharmaceutical Co Adr
|
17.24 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.78 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.81 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.35 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
528.47 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-23 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-12-19 | 다운그레이드 | Nomura | Buy → Neutral |
| 2024-01-11 | 다운그레이드 | Jefferies | Buy → Underperform |
| 2023-08-29 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-05-18 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2023-03-17 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-01-30 | 개시 | JP Morgan | Underweight |
| 2022-11-14 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2022-01-03 | 재개 | BofA Securities | Neutral |
| 2021-07-27 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2021-02-02 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-09-18 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-09-18 | 업그레이드 | Investec | Sell → Hold |
| 2020-01-28 | 다운그레이드 | CLSA | Buy → Outperform |
| 2020-01-27 | 다운그레이드 | CLSA | Buy → Outperform |
| 2020-01-09 | 업그레이드 | Citigroup | Sell → Buy |
| 2019-11-04 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-09-04 | 업그레이드 | Credit Suisse | Underperform → Outperform |
| 2019-07-01 | 업그레이드 | Macquarie | Neutral → Outperform |
| 2019-06-20 | 개시 | Deutsche Bank | Hold |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-20 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-02-19 | 업그레이드 | CLSA | Outperform → Buy |
| 2019-01-17 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2017-09-21 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-08-31 | 업그레이드 | CLSA | Underperform → Outperform |
| 2017-07-28 | 다운그레이드 | CLSA | Underperform → Sell |
| 2016-07-27 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2016-07-27 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2016-02-10 | 업그레이드 | Credit Agricole | Underperform → Buy |
| 2015-11-10 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
Dr Reddys Laboratories Ltd Adr 주식(RDY)의 최신 뉴스
HDFC Bank Limited (HDB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Dr. Reddy’s Labs ADR earnings missed by $0.03, revenue fell short of estimates By Investing.com - Investing.com South Africa
Dr Reddy's share price: Why this stock plunged 9% today; more downside ahead? - Business Today
Dr. Reddy's Labs shares fall 4% after weak Q1 results; Profit slumps 69%, margins shrink - Business Upturn
Dr Reddy's Labs share price to track 9% ADR fall; targets by CLSA, Nomura, Goldman Sachs, Citi, others - Business Today
Q1 Results LIVE Updates: Infosys, Cipla, IndiGo report today; Dr Reddy's ADR tanks 10% - CNBC TV18
Dr. Reddy's Laboratories shares fall 7% as most analysts remain bearish after Q1 earnings miss - CNBC TV18
Dr. Reddy’s Labs ADR earnings missed by $0.03, revenue fell short of estimates - Investing.com India
Dr. Reddy's Earnings: Reduced Lenalidomide Sales and Semaglutide Challenge Mark a Weak Start to Year - Morningstar
Dr. Reddy's Starts Year on Weak Ground as Lenalidomide and Semaglutide Impacts Weigh on Results - Morningstar
Earnings call transcript: Dr. Reddy’s misses Q1 2026 EPS forecast as stock falls 8% - Investing.com
Dr Reddy’s ADR falls 5% as profit drops sharplyCheck details - CNBC TV18
Dr Reddy’s ADR falls over 5% after Q1 results miss analyst estimates despite already muted expectations - Business Upturn
ASML Holding N.V. Upgraded, Super Micro Computer Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Antiparasitic Drugs Market Report Released — Examines Antimalarials, Anthelmintics, Antiprotozoals, Ectoparasiticides, and Neglected Tropical Disease Therapies - GlobeNewswire Inc.
Price to earnings forward of Dr. Reddy's Laboratories Ltd. Sponsored ADR – MUN:RDDA - TradingView
Korea’s SK Hynix makes history in US – raises $26.5 billion in largest foreign debut - financialexpress.com
SK Hynix plans to price its US listing at $149 - financialexpress.com
Dr Reddy's Shares Slide Over 6% After Semaglutide Batch Quality Concern - NDTV Profit
Dr. Reddy's Labs ADR highlights its global generics footprint as investors track U.S. healthcare dem - ad-hoc-news.de
Dr. Reddy's Labs ADR highlights global generics reach. Investors look at U.S. listing context - AD HOC NEWS
RDY News | DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - ChartMill
Full Transcript: Dr Reddy's Laboratories Q4 2026 Earnings Call - Sahm
Eli Lilly Upgraded, Carvana Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Dr. Reddy’s Laboratories files FY26 annual report with US SEC - scanx.trade
RDDA Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Dr. Reddy's Laboratories Ltd. Sponsored ADR – MUN:RDDA - TradingView
Enterprise value to EBITDA forward of Dr. Reddy's Laboratories Ltd. Sponsored ADR – MUN:RDDA - TradingView
Dr. Reddy's Labs ADR files Form 20-F, shares stay tied to US pharma peers - AD HOC NEWS
Enterprise value to EBIT forward of Dr. Reddy's Laboratories Ltd. Sponsored ADR – MUN:RDDA - TradingView
Dr. Reddy's Laboratories Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR - TradingView
Dr. Reddy’s files 2026 annual report with the SEC - Stock Titan
659157 Forecast — Price Target — Prediction for 2027 - TradingView
Form 6K DR REDDYS LABORATORIES LTD For: 22 June By Investing.com - Investing.com Nigeria
Form 6K Kinross Gold Corp For: 22 June By Investing.com - Investing.com Nigeria
Dr. Reddy’s (NYSE: RDY) allots 6,730 ESOP shares to employees - Stock Titan
Why Dr. Reddy's Venlafaxine XR capsules quietly matter for everyday patients - AD HOC NEWS
Dr. Reddy’s Allots 6,730 ESOP Shares, Expands Issued Capital - TipRanks
Why Dr. Reddy’s Celevida Maxx matters for Indian diabetics - AD HOC NEWS
NIFTY50, SENSEX today: Wall Street cues, FII activity, key things to know before markets open on June 19 - Upstox
Dr. Reddy's Labs (ADR) Stock (US2565981035): Earnings and valuation keep the ADR in focus - ad-hoc-news.de
Dr. Reddy's Laboratories Ltd Stock (INE089A01023): U.S. Bosutinib Launch And Pre-market Drop Put ADR - Ad-hoc-news.de
Dr. Reddy's Laboratories stock (INE089A01023): focus on recent FDA progress and US generics growth - Ad-hoc-news.de
With Lenalidomide Headwinds Behind, Dr. Reddy's Turns to Biosimilars and Consumer Health for Growth - Morningstar
Dr. Reddy’s (NYSE: RDY) allots 12,100 ESOP shares, updates capital - Stock Titan
Dr. Reddy’s Laboratories issues 12,100 equity shares under stock options scheme - Business Upturn
Topicus submits revised $2.00 per share proposal for ReadyTech By Investing.com - Investing.com UK
Topicus submits revised $2.00 per share proposal for ReadyTech - Investing.com UK
Dr Reddys Laboratories Ltd Adr (RDY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
0.52%
자본화:
|
볼륨(24시간):